Frede Donskov

Aarhus University Hospital — Denmark

Medicine · Health Sciences

62h-index28.8kcitations369works14.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Renal cell carcinoma treatment(301), Cancer Genomics and Diagnostics(138), Renal and related cancers(128), Cancer Immunotherapy and Biomarkers(72), Economic and Financial Impacts of Cancer(58)

Publications369 total

Outcomes of Patients with Metastatic Non–clear Cell Renal Cell Carcinoma Receiving Contemporary or Traditional First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
European Urology Oncology·2026Open Access
Attrition Rates in Metastatic Renal Cell Carcinoma (mRCC) Following First Line Immunotherapy-Based Treatment: Results From the International mRCC Database Consortium (IMDC)
Clinical Genitourinary Cancer·2025
2629P Durability of Complete Response (CR) to first-line (1L) in metastatic renal cell carcinoma (mRCC) in the real world
Annals of Oncology·2025
Therapeutic drug monitoring (TDM) of tyrosine kinase inhibitors (TKI) for optimized outcome in patients with metastatic renal cell carcinoma. The TKI-TDM Trial. Study protocol
Acta Oncologica·2025· 2 citedOpen Access
Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: Final analysis from the phase 3 CheckMate 214 trial.
Journal of Clinical Oncology·2025· 13 cited
International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) classification and regression tree analysis to characterize objective response rates (ORR) in metastatic renal cell carcinoma (mRCC).
Journal of Clinical Oncology·2025
Outcomes based on risk-adapted adjuvant therapy in postmenopausal women with early breast cancer: a nationwide, prospective cohort study by the Danish Breast Cancer Group
The Lancet Oncology·2025· 3 cited
Updated outcomes of patients with metastatic non-clear cell renal cell carcinoma (mnccRCC) treated with first-line (1L) therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
Journal of Clinical Oncology·2025· 1 cited
Cabozantinib real-world effectiveness in the second-line setting of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
Journal of Clinical Oncology·2025
Compassion training for healthcare professionals in oncology: A mixed-methods pilot study
European Journal of Oncology Nursing·2025
Role of the Microbiome and Diet for Response to Cancer Checkpoint Immunotherapy: A Narrative Review of Clinical Trials
Current Oncology Reports·2025· 16 citedOpen Access
Soluble CD206 in metastatic renal cell carcinoma: Relation to clinical–biochemical parameters and patient outcome
International Journal of Cancer·2024· 2 citedOpen Access
8 Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: 8-year follow-up with analyses in favorable risk patients from the phase 3 CheckMate 214 trial
The Oncologist·2024· 2 citedOpen Access
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial
Annals of Oncology·2024· 144 citedOpen Access
Cabozantinib Induces Isolated Hyperbilirubinemia in Renal Cell Carcinoma Patients carrying the UGT1A1*28 Polymorphism
Clinical Genitourinary Cancer·2024· 1 cited
Development and Methodological Validation of a Modified Staging System for de Novo Metastatic Breast Cancer
JAMA Network Open·2024· 5 citedOpen Access
Cytoreductive Nephrectomy in Select Primary Metastatic Renal Cell Carcinoma Patients: A Comprehensive Nationwide Outcome Analysis
Cancers·2024· 2 citedOpen Access
Multicenter randomized trial of deferred cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma receiving checkpoint inhibitors: the NORDIC-SUN-Trial
BMC Cancer·2024· 35 citedOpen Access
Nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): Long-term follow-up data from the phase 3 CheckMate 214 trial.
Journal of Clinical Oncology·2024· 44 cited
Treatment-free survival after first-line therapies for metastatic renal cell carcinoma: An International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) analysis.
Journal of Clinical Oncology·2024
page 1 of 19Next →

Frequent Co-authors

Toni K. Choueiri(29), Brian I. Rini(28), Robert J. Motzer(22), David F. McDermott(18), Bernard Escudier(17), Georg A. Bjarnason(17), Christian Kollmannsberger(16), Jae‐Lyun Lee(14), Daniel Y.C. Heng(14), Thomas Powles(13), Lori Wood(13), Hans J. Hammers(12), Sumanta K. Pal(12), Saby George(11), Elizabeth R. Plimack(11), Howard Gurney(11), Nizar M. Tannir(11), Camillo Porta(11), Yoshihiko Tomita(10), Alain Ravaud(10)